Login / Signup

Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.

JaeJin AnFang NiuJohn J Sim
Published in: Pharmacotherapy (2021)
Among patients with DKD and hypertension, the short-term use of MRAs, either spironolactone or eplerenone, in combination with ACEI/ARBs, was not associated with lower risk of cardiovascular or kidney outcomes compared with ACEI/ARB monotherapy. The risk of hyperkalemia and the short duration of combination therapy may suggest a real-world clinical challenge for MRA with ACEI/ARB combination therapy.
Keyphrases
  • combination therapy
  • blood pressure
  • type diabetes
  • clinical trial
  • computed tomography
  • metabolic syndrome
  • contrast enhanced
  • adipose tissue
  • study protocol
  • open label
  • glycemic control
  • arterial hypertension